Full length parathyroid hormone (1–84) in the treatment of osteoporosis in postmenopausal women
Authors Esteban Jódar-Gimeno
Published 15 April 2007 Volume 2007:2(1) Pages 163—174
Endocrinology and Metabolism Service, University Hospital “12 de Octubre”, Madrid, Spain. Associate Professor of Medicine Universidad Complutense, Madrid, Spain
Objective: To review the pharmacological properties and the available clinical data of full length parathyroid hormone (PTH) in post-menopausal osteoporosis.
Sources: A MEDLINE search was completed, together with a review of information obtained from the manufacturer and from the medicine regulatory agencies.
Study and data selection: Studies were selected according to relevance and availability. Relevant information (design, objectives, patients’ characteristics, outcomes, adverse events, dosing, etc) was analyzed.
Results: Different studies have shown that, when administered intermittently as a subcutaneous injection in the abdomen, PTH increases bone mineral density (BMD) and prevents vertebral fractures. On completion of PTH therapy (up to 24 months), there is evidence that sequential treatment with alendronate is associated with a therapeutic benefit in terms of increase in BMD. Further trials are necessary to determine long-term safety and the role of PTH in combination with other treatments for osteoporosis and the effect of repeated cycles of PTH followed by an anti-catabolic agent. There are currently no completed comparative trials with other osteoporosis treatments.
Conclusions: Full length PTH, given intermittently as an abdominal subcutaneous injection, appears to be a safe and efficacious treatment option for high risk osteoporosis. More data are needed to determine its specific role in osteoporosis treatment.
Keywords: postmenopausal osteoporosis, anabolic therapy, PTH (1–84)
Readers of this article also read:
Preparation, characterization, and in vivo study of rhein-loaded poly(lactic-co-glycolic acid) nanoparticles for oral delivery
Yuan Z, Gu XH
Published Date: 21 April 2015
Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies
Linder M, BystrΓΆm C, Kieler H, Bergman G, Haerskjold A
Published Date: 29 December 2014
Effects of adsorbed and templated nanosilver in mesoporous calcium-silicate nanoparticles on inhibition of bacteria colonization of dentin
Fan W, Wu D, Tay FR, Ma T, Wu Y, Fan B
Published Date: 12 November 2014
Associations between apolipoprotein E genotypes and serum levels of glucose, cholesterol, and triglycerides in a cognitively normal aging Han Chinese population
Tao QQ, Chen Y, Liu ZJ, Sun YM, Yang P, Lu SJ, Xu M, Dong QY, Yang JJ, Wu ZY
Published Date: 9 July 2014
Virgin olive oil blended polyurethane micro/nanofibers ornamented with copper oxide nanocrystals for biomedical applications
Amna T, Hassan MS, Yang J, Khil MS, Song KD, Oh JD, Hwang I
Published Date: 13 February 2014
Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo [Corrigendum]
Xiang DX, Zheng Y, Duan W, Li XJ, Yin JJ, Shigdar S, O'Connor ML, Marappan M, Zhao XJ, Miao YQ, Xiang B, Zheng CL
Published Date: 5 December 2013
Microincisional vitrectomy for retinal detachment in I-125 brachytherapy-treated patients with posterior uveal malignant melanoma
Lonngi M, Houston SK, Murray TG, Sisk RA, Decatur CL, Cavalcante M, Markoe AM
Published Date: 27 February 2013
Development and utility of pirfenidone in the treatment of idiopathic pulmonary fibrosis: review of preclinical science and recent clinical trials
Jackson RM, Gomez-Marin O
Published Date: 11 April 2011
Persistent high fever and systemic inflammation induced by percutaneous coronary intervention-related periaortitis
Takamori Kakino, Tomohiro Nakayama, Hideo Yamamoto
Published Date: 8 December 2009
Angie Veverka, Jennifer L Salinas
Published Date: 15 November 2007